CL2009001158A1 - Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. - Google Patents
Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.Info
- Publication number
- CL2009001158A1 CL2009001158A1 CL2009001158A CL2009001158A CL2009001158A1 CL 2009001158 A1 CL2009001158 A1 CL 2009001158A1 CL 2009001158 A CL2009001158 A CL 2009001158A CL 2009001158 A CL2009001158 A CL 2009001158A CL 2009001158 A1 CL2009001158 A1 CL 2009001158A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazole
- cancer
- pharmaceutical composition
- treatment
- protein kinase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- NXWGUROSVPLYQB-UHFFFAOYSA-N 1h-furo[3,2-c]pyrazole Chemical compound N1N=CC2=C1C=CO2 NXWGUROSVPLYQB-UHFFFAOYSA-N 0.000 title 1
- FKWUPVHNVKGGSD-UHFFFAOYSA-N 1h-thieno[2,3-c]pyrazole Chemical compound C1=NNC2=C1C=CS2 FKWUPVHNVKGGSD-UHFFFAOYSA-N 0.000 title 1
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
Abstract
Compuestos derivados de carbonilamino(1-2)pirazol biciclicosustituido; composición farmacéutica; útiles en el tratamiento del cáncer, mediados por la alteración de una proteína quinasa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156262 | 2008-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001158A1 true CL2009001158A1 (es) | 2009-10-23 |
Family
ID=40886839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001158A CL2009001158A1 (es) | 2008-05-15 | 2009-05-13 | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20110118278A1 (es) |
| EP (1) | EP2300436B1 (es) |
| JP (1) | JP5984387B2 (es) |
| KR (1) | KR101586634B1 (es) |
| CN (1) | CN102026983B (es) |
| AR (1) | AR071780A1 (es) |
| AU (1) | AU2009248060B2 (es) |
| BR (1) | BRPI0911986A2 (es) |
| CA (1) | CA2724215C (es) |
| CL (1) | CL2009001158A1 (es) |
| EA (1) | EA019901B1 (es) |
| ES (1) | ES2689325T3 (es) |
| IL (1) | IL209234A (es) |
| MX (1) | MX2010012295A (es) |
| NZ (1) | NZ589956A (es) |
| SG (1) | SG190636A1 (es) |
| TW (1) | TW201004951A (es) |
| UA (1) | UA106353C2 (es) |
| WO (1) | WO2009138440A1 (es) |
| ZA (1) | ZA201008911B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2120932B1 (en) * | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| KR101178495B1 (ko) | 2010-05-03 | 2012-09-07 | 서울대학교산학협력단 | 3,6-이치환-4,5,6,7-테트라하이드로-1H-피라졸로[3,4-c]피리딘-7-온 화합물과 이 화합물의 제조방법 |
| KR101953272B1 (ko) * | 2011-05-12 | 2019-02-28 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서 활성인 치환된 인다졸 유도체 |
| WO2015110467A1 (en) * | 2014-01-23 | 2015-07-30 | Nerviano Medical Sciences S.R.L. | Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3464286B1 (en) | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| CN115073471B (zh) * | 2021-03-11 | 2023-03-21 | 沈阳药科大学 | 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用 |
| CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05009719A (es) * | 2003-03-11 | 2005-10-18 | Pharmacia Italia Spa | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TW200526204A (en) * | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| WO2007009898A1 (en) * | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
| US7947686B2 (en) * | 2005-12-12 | 2011-05-24 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors |
| WO2007068637A1 (en) * | 2005-12-12 | 2007-06-21 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| WO2007138017A1 (en) * | 2006-05-31 | 2007-12-06 | Nerviano Medical Sciences S.R.L. | 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
| WO2008043745A1 (en) * | 2006-10-11 | 2008-04-17 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| JP5451602B2 (ja) * | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての5−ヘテロアリール置換インダゾール類 |
-
2009
- 2009-05-13 CL CL2009001158A patent/CL2009001158A1/es unknown
- 2009-05-13 AR ARP090101726A patent/AR071780A1/es unknown
- 2009-05-14 CN CN200980117463.3A patent/CN102026983B/zh not_active Expired - Fee Related
- 2009-05-14 MX MX2010012295A patent/MX2010012295A/es active IP Right Grant
- 2009-05-14 EA EA201071307A patent/EA019901B1/ru not_active IP Right Cessation
- 2009-05-14 US US12/991,564 patent/US20110118278A1/en not_active Abandoned
- 2009-05-14 WO PCT/EP2009/055802 patent/WO2009138440A1/en not_active Ceased
- 2009-05-14 NZ NZ589956A patent/NZ589956A/xx not_active IP Right Cessation
- 2009-05-14 EP EP09745772.5A patent/EP2300436B1/en not_active Not-in-force
- 2009-05-14 SG SG2013034996A patent/SG190636A1/en unknown
- 2009-05-14 KR KR1020107028088A patent/KR101586634B1/ko not_active Expired - Fee Related
- 2009-05-14 BR BRPI0911986A patent/BRPI0911986A2/pt not_active Application Discontinuation
- 2009-05-14 UA UAA201015066A patent/UA106353C2/ru unknown
- 2009-05-14 AU AU2009248060A patent/AU2009248060B2/en not_active Ceased
- 2009-05-14 JP JP2011508911A patent/JP5984387B2/ja not_active Expired - Fee Related
- 2009-05-14 CA CA2724215A patent/CA2724215C/en not_active Expired - Fee Related
- 2009-05-14 ES ES09745772.5T patent/ES2689325T3/es active Active
- 2009-05-14 TW TW098115969A patent/TW201004951A/zh unknown
-
2010
- 2010-11-10 IL IL209234A patent/IL209234A/en active IP Right Grant
- 2010-12-10 ZA ZA2010/08911A patent/ZA201008911B/en unknown
-
2012
- 2012-09-28 US US13/630,009 patent/US8809337B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2300436B1 (en) | 2018-07-18 |
| ZA201008911B (en) | 2012-02-29 |
| AU2009248060A1 (en) | 2009-11-19 |
| BRPI0911986A2 (pt) | 2015-10-13 |
| IL209234A0 (en) | 2011-01-31 |
| CA2724215C (en) | 2016-03-29 |
| AU2009248060B2 (en) | 2013-11-14 |
| SG190636A1 (en) | 2013-06-28 |
| UA106353C2 (en) | 2014-08-26 |
| KR20110009706A (ko) | 2011-01-28 |
| JP5984387B2 (ja) | 2016-09-06 |
| US20130203770A1 (en) | 2013-08-08 |
| EA201071307A1 (ru) | 2011-06-30 |
| EP2300436A1 (en) | 2011-03-30 |
| HK1151793A1 (en) | 2012-02-10 |
| ES2689325T3 (es) | 2018-11-13 |
| US8809337B2 (en) | 2014-08-19 |
| CN102026983B (zh) | 2014-10-22 |
| WO2009138440A1 (en) | 2009-11-19 |
| NZ589956A (en) | 2012-11-30 |
| JP2011520838A (ja) | 2011-07-21 |
| AR071780A1 (es) | 2010-07-14 |
| KR101586634B1 (ko) | 2016-01-20 |
| MX2010012295A (es) | 2010-12-06 |
| CA2724215A1 (en) | 2009-11-19 |
| US20110118278A1 (en) | 2011-05-19 |
| CN102026983A (zh) | 2011-04-20 |
| EA019901B1 (ru) | 2014-07-30 |
| TW201004951A (en) | 2010-02-01 |
| IL209234A (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001158A1 (es) | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. | |
| PE20211001A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| UY37700A (es) | Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| ECSP17027306A (es) | Derivados de imidazol pentacíclicos fusionados | |
| CA2931589C (en) | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity | |
| NI201800141A (es) | Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4 | |
| CL2010001363A1 (es) | Compuestos derivados de 1h-pirrolo[piridina o pirimidina], moduladores del receptores grucocorticoides; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento de enfermedades tales como diabetes tipo ii, obesidad e hipertension, entre otras | |
| CR20120273A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA | |
| PH12014500794A1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| BR112016013012A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| CL2015002386A1 (es) | Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo. | |
| CL2013001464A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras. | |
| WO2013077921A3 (en) | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof | |
| CL2007003629A1 (es) | Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos. | |
| WO2011103460A8 (en) | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use | |
| CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
| MX352927B (es) | Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa. | |
| CL2008001025A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer. | |
| CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| EA201190142A1 (ru) | Производные пиразола, используемые в качестве антагонистов рецептора ccr4 | |
| CL2008002747A1 (es) | Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros. | |
| TR201910983T4 (tr) | Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. |